Andera Partners
Investor profile
Venture capital
Andera Partners has backed 21 European tech companies across 28 funding rounds between 2018 and 2026, joining rounds totalling €2.0B. Most active in Healthtech and Energy. Data as of Nov 2026.
Deals
28
distinct rounds
Companies
21
backed
Active span
2018–2026
9 yrs
Total round €
€2.0B
sum of rounds joined
Deals by year
distinct rounds / yearAndera Partners — deals by year — interactive chart.
Data table
| Andera Partners — deals by year | |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 3 |
Top sectors
by dealsAndera Partners — top sectors — interactive chart.
Data table
| Andera Partners — top sectors | |
|---|---|
| Healthtech | 19 |
| Energy | 4 |
| Software | 3 |
| AI | 1 |
| Transportation | 1 |
Stages
by dealsAndera Partners — stages — interactive chart.
Data table
| Andera Partners — stages | |
|---|---|
| Other | 11 |
| Series B | 7 |
| Series A | 5 |
| Series C | 3 |
| Debt | 1 |
| Series D+ | 1 |
Countries
by dealsAndera Partners — countries — interactive chart.
Data table
| Andera Partners — countries | |
|---|---|
| France | 11 |
| Germany | 5 |
| UK | 3 |
| Ireland | 2 |
| Italy | 2 |
| Netherlands | 2 |
| Belgium | 1 |
| Spain | 1 |
| Switzerland | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- EQT Life Sciences5
- FundPlus4
- Seventure Partners4
- Sofinnova Partners4
- Earlybird Venture Capital3
- GIMV3
- Novo Holdings3
- Pfizer Ventures3
- Bayern Kapital2
- Bpifrance2
- British Patient Capital2
- Canaan Partners2
- Curie Capital2
- FIRST Fund2
- Gilde Healthcare2
- Hadean Ventures2
- High-Tech Gründerfonds (HTGF)2
- INKEF Capital2
- Invus2
- Ireland Strategic Investment Fund2
- LBBW Venture Capital GmbH2
- Lightstone Ventures2
- M Ventures2
- Medtronic2
- OCCIDENT2
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Tubulis Technologies | Germany | 2 | €368M |
| HR Path | France | 3 | €325M |
| Fire1 | Ireland | 2 | €139M |
| Amolyt Pharma | France | 1 | €129M |
| Nouscom | Switzerland | 1 | €120M |
| HighLife | France | 2 | €112M |
| Mylight150 | France | 1 | €100M |
| Artios | UK | 1 | €99M |
| Imcheck Therapeutics | France | 1 | €96M |
| T-knife | Germany | 1 | €93M |
| Grey Wolf Therapeutics | UK | 2 | €87M |
| Exciva | Germany | 2 | €60M |
| SoniVie | Italy | 1 | €56M |
| Qovoltis | France | 1 | €45M |
| Bioptimus | France | 1 | €40M |
| TargED Biopharmaceuticals | Netherlands | 1 | €39M |
| TargED Biopharmaceutical | Netherlands | 1 | €39M |
| Ingenostrum | Spain | 1 | €25M |
| Medical microinstruments | Italy | 1 | €20M |
| Skysun | Belgium | 1 | €17M |
| Klubb | France | 1 | €0 |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Tubulis Technologies | Series C | €308M | 2025-10 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| Fire1 | Other | €115M | 2025-01 |
| HR Path | Other | €113M | 2022-05 |
| HR Path | Debt | €113M | 2022-05 |
| HR Path | Other | €100M | 2019-04 |
| Mylight150 | Other | €100M | 2023-11 |
| Artios | Series D+ | €99M | 2025-11 |
| Imcheck Therapeutics | Other | €96M | 2022-06 |
| T-knife | Series B | €93M | 2021-08 |